eFFECTOR Therapeutics Stock

effector.comHealthcare / BioTech & PharmaFounded: 2012Funding to Date: $152.08MM

eFFECTOR Therapeutics is a clinical-stage biopharmaceutical company focused on pioneering the discovery and development of a new class of oncology drugs known as selective translation regulators (STRs).

Register To Buy and Sell Shares

For more details on financing and valuation for eFFECTOR Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access eFFECTOR Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like eFFECTOR Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Stephen Worland Ph.D
Chief Executive Officer, President, Board Member & Co-Founder
Davide Ruggero Ph.D
Kevin Webster Ph.D
Senior Vice President of Cancer Biology
Alana McNulty
Chief Financial Officer
Debra Vallner Ph.D
Vice President of Development Operations
Kevan Shokat Ph.D
Co-Founder and Member of Scientific Advisory Board
Siegfried Reich Ph.D
Senior Vice President, Research & Co-Founder
Annette Matthies Ph.D
Vice President of Corporate Development
Jeremy Barton MD
Chief Medical Officer

Board Members

David Maki JD
Altitude Life Science Ventures
Ken Haas JD
Markus Goebel Ph.D
Novartis Venture Fund
Elaine Jones Ph.D
Pfizer Ventures
Laurence Lasky Ph.D
US Venture Partners
Stephen Worland Ph.D
Jonathan Root MD
US Venture Partners
KT Moortgat Ph.D
AbbVie Ventures
Simeon George MD
SR One

News Highlights

Locust Walk Acquisition Corp.’s Stockholders Approve Business Combination with eFFECTOR Therapeutics to Create Next-Generation Oncology Company Developing New Class of Cancer Therapies
Locust Walk Acquisition Corp. (NASDAQ: LWAC) (“LWAC” or the “Company”), a special purpose acquisition company, announced today that the Company’s stockholders have approved all proposals related to the previously announced business combination (the “Business Combination”) with eFFECTOR Therapeutics, Inc. (“eFFECTOR”) at a special meeting of stockholders held on August 24, 2021. Approximately 93.2% of the votes cast at the meeting on the Business Combination proposal, representing approximately 71.7% of LWAC’s outstanding shares, voted to approve the Business Combination.
Xconomy: Effector Raises $38.6M to Advance New Class of Anti-Cancer Drugs
San Diego’s Effector Therapeutics, a five-year-old cancer drug developer, has raised $38.6 million in new venture capital funding. The Series C financing,
eFFECTOR Therapeutics Increases its Series B Financing Round to $56M
/PRNewswire/ -- eFFECTOR Therapeutics, Inc., a biopharmaceutical company developing selective translation regulators for the treatment of cancer, today...
Updated on: Apr 14, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.